• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by iTeos Therapeutics Inc.

    3/6/24 7:19:17 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ITOS alert in real time by email
    S-8 1 itos_march_2024_evergree.htm S-8 S-8

     

     

    As filed with the Securities and Exchange Commission on March 6, 2024

     

    Registration No. 333-

     

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT

    Under

     

    The Securities Act of 1933

     

     

     

    iTeos Therapeutics, Inc.

     

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    37-3365066

    (State or other jurisdiction of

    (I.R.S. Employer

    incorporation or organization)

    Identification No.)

     

    321 Arsenal Street

    Watertown, MA 02472

    (339) 217-0162

     

    (Address of Principal Executive Offices) (Zip Code)

     

    iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan, as Amended

     

     

    (Full title of the plan)

     

    Michel Detheux, Ph.D.

     

    Chief Executive Officer

     

    iTeos Therapeutics, Inc.

     

    321 Arsenal Street

    Watertown, MA 02472

     

    (339) 217-0162

     

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Paul Kinsella

    William Michener

    Ropes & Gray LLP

    Prudential Tower

    800 Boylston Street

    Boston, MA 02199-3600

    (617) 951-7000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement is filed to register an additional 1,791,904 shares of the Registrant’s common stock, par value $0.001 per share, for issuance under the iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan, as amended. This Registration Statement is being filed in accordance with General Instruction E to Form S-8 regarding registration of additional securities of the same class, and, pursuant to such instruction, the contents of the Registration Statements on Form S-8 (Registration Nos. 333-240144, 333-254670, 333-263791, and 333-270545) filed with the Securities and Exchange Commission on July 28, 2020, March 23, 2021, March 23, 2022, and March 15, 2023, respectively, are incorporated herein by reference.

     


     

    Part II

    Item 8. Exhibits.

     

    Exhibit

    No.

     

    Description

     

     

     

    4.1

     

    Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-39401) filed with the Securities and Exchange Commission on July 28, 2020).

     

     

     

    4.2

     

    Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K (File No. 001-39401) filed with the Securities and Exchange Commission on July 28, 2020).

     

     

     

    4.3

     

    Amended and Restated Stockholders’ Agreement, dated as of March 24, 2020 (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed with the Securities and Exchange Commission on July 20, 2020).

     

     

     

    4.4

     

    Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-239415) filed on July 20, 2020).

     

     

     

    4.5

     

    2020 Stock Option and Incentive Plan, as amended (Incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39401) filed with the Securities and Exchange Commission on June 13, 2022)).

     

     

     

    4.6

     

    Forms of Award Agreements under the 2020 Stock Option and Incentive Plan (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-239415)).

     

     

     

    5.1*

     

    Opinion of Ropes & Gray LLP.

     

     

     

    23.1*

     

    Consent of Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises BV/SRL.

     

     

     

    23.2*

     

    Consent of Ropes & Gray LLP (included in Exhibit 5.1).

     

     

     

    24.1*

     

    Power of Attorney (included on signature page).

     

     

     

    107*

     

    Calculation of Filing Fee Table.

     

    * Filed herewith.

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, State of Massachusetts, on this 6th day of March, 2024.

     

    ITEOS THERAPEUTICS, INC.

     

    By: /s/ Michel Detheux

     

     

    Name: Michel Detheux

     

    Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michel Detheux and Matthew Gall, and each of them, either of whom may act without the joinder of the other, as his true and lawful attorneys-in-fact and agents with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Name

    Title

    Date

    /s/ Michel Detheux

    Chief Executive Officer and Director

    March 6, 2024

    Michel Detheux

    (Principal Executive Officer)

     

    /s/ David L. Hallal

    Director and Chairman of the Board of Directors

    March 6, 2024

    David L. Hallal

     

     

    /s/ Matthew Gall

    Chief Financial Officer (Principal Financial Officer and

    March 6, 2024

    Matthew Gall

    Principal Accounting Officer)

     

    /s/ Aaron Davis

    Director

    March 6, 2024

    Aaron Davis

     

     

    /s/ Tim Van Hauwermeiren

    Director

    March 6, 2024

    Tim Van Hauwermeiren

     

     

    /s/ Tony Ho

    Director

    March 6, 2024

    Tony Ho

     

     

    /s/ Robert Iannone

    Director

    March 6, 2024

    Robert Iannone

     

     

    /s/ David. K. Lee

    Director

    March 6, 2024

    David K. Lee

     

     

    /s/ Ann D. Rhoads

    Director

    March 6, 2024

    Ann D. Rhoads

     

     

     

     

     

     

     


    Get the next $ITOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITOS

    DatePrice TargetRatingAnalyst
    5/28/2025$12.00Overweight → Equal Weight
    Wells Fargo
    5/28/2025$12.00Outperform → Neutral
    Wedbush
    5/14/2025$9.00Outperform → Market Perform
    Leerink Partners
    5/14/2025Buy → Neutral
    H.C. Wainwright
    5/13/2025Overweight → Neutral
    Analyst
    8/13/2024$31.00Overweight
    Wells Fargo
    12/13/2021$37.00 → $54.00Buy
    HC Wainwright & Co.
    11/12/2021$55.00 → $54.00Outperform
    SVB Leerink
    More analyst ratings

    $ITOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Call Matthew closing all direct ownership in the company (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    8/29/25 4:30:31 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Detheux Michel closing all direct ownership in the company (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    8/29/25 4:30:29 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Lee David K

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    8/29/25 4:30:26 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

    WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (NASDAQ:ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share ("iTeos Common Stock"), plus one non-transferable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing (such cash

    7/21/25 7:29:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Therapeutics Announces Its Intention to Wind Down Operations

    - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Following a thorough

    5/28/25 8:30:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

    – GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported topline results from an updated interim analysis of GALAXIES Lung-201, the Phase 2 platform s

    5/13/25 7:55:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    SEC Filings

    View All

    SEC Form 15-12G filed by iTeos Therapeutics Inc.

    15-12G - iTeos Therapeutics, Inc. (0001808865) (Filer)

    9/8/25 4:15:45 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by iTeos Therapeutics Inc.

    EFFECT - iTeos Therapeutics, Inc. (0001808865) (Filer)

    9/5/25 12:15:04 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by iTeos Therapeutics Inc.

    SCHEDULE 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    9/3/25 4:15:17 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iTeos Therapeutics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded iTeos Therapeutics from Overweight to Equal Weight and set a new price target of $12.00

    5/28/25 10:52:33 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Therapeutics downgraded by Wedbush with a new price target

    Wedbush downgraded iTeos Therapeutics from Outperform to Neutral and set a new price target of $12.00

    5/28/25 10:12:02 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded iTeos Therapeutics from Outperform to Market Perform and set a new price target of $9.00

    5/14/25 8:56:56 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ecor1 Capital, Llc bought $38,685,562 worth of shares (4,958,978 units at $7.80) (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    5/16/25 6:52:07 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Gall Matthew bought $38,635 worth of shares (5,000 units at $7.73), increasing direct ownership by 8% to 65,429 units (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    11/19/24 7:59:14 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gall Matthew bought $41,850 worth of shares (5,000 units at $8.37), increasing direct ownership by 35% to 19,429 units (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    10/12/23 5:09:33 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iTeos Therapeutics Inc.

    SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/21/24 8:27:38 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

    SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/19/24 9:57:32 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

    SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/18/24 9:57:13 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Leadership Updates

    Live Leadership Updates

    View All

    iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

    WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies. "As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we're excited to welcome Dr. Feltquate as Chief Medical Officer," said Michel Detheux, Ph.D., presi

    8/5/24 7:00:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

    WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company's audit committee. "Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos. After the recent appointment of Servier's David Lee, we are thrilled to welcome Jill DeSimone to o

    3/6/24 7:01:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

    - Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Completed enrollment of third dose cohort in Phase 1 trial of EOS-984- Preclinical presentations on role of ENT1 at SITC Spring Scientific and profile of EOS-984 at AACR annual meeting- Cash and investment balance of $632.7 million as of December 31, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones- Oncology veterans Jill DeSimone and David K. Lee to join Board of Directors WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NA

    3/6/24 7:00:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ITOS
    Financials

    Live finance-specific insights

    View All

    iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

    - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stag

    9/14/24 2:30:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

    - First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors - Advanced clinical development of inupadenant, EOS-850, an A2A receptor antagonist, with initiation of an expansion in PD-1 resistant melanoma in combination with pembrolizumab as well as a planned study further exploring novel predictive biomarkers - Received full upfront payment of $625MM at closing of development and commercialization collaboration agreement with GSK for EOS-448 - Cash balance of $899.8MM as of September 30, 2021, providing runway into 2026 to support clinical development plans for EOS-448 and inupad

    11/10/21 4:01:00 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 833-927-1758 (domestic) or 929-526-1599 (international) and refer to conference access code 861337. A live audio webcast of the event will also be accessible from

    11/3/21 7:00:00 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care